Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 406

1.

Precision cancer therapy is impacted by oncogene-dependent epigenome remodeling.

Liu F, Mischel PS, Cavenee WK.

NPJ Precis Oncol. 2017 Mar 20;1(1):1. doi: 10.1038/s41698-017-0005-2. eCollection 2017. Review.

2.

Benefit of Apabetalone on Plasma Proteins in Renal Disease.

Wasiak S, Tsujikawa LM, Halliday C, Stotz SC, Gilham D, Jahagirdar R, Kalantar-Zadeh K, Robson R, Sweeney M, Johansson JO, Wong NC, Kulikowski E.

Kidney Int Rep. 2017 Dec 8;3(3):711-721. doi: 10.1016/j.ekir.2017.12.001. eCollection 2018 May.

3.

Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages.

de Groot AE, Pienta KJ.

Oncotarget. 2018 Feb 21;9(29):20908-20927. doi: 10.18632/oncotarget.24556. eCollection 2018 Apr 17. Review.

4.

NUT carcinoma of the sinonasal tract infiltrating the orbit in a man with birdshot chorioretinitis.

Chan W, Bullock MJ, Samad AF, Archibald CW, Heathcote JG.

Saudi J Ophthalmol. 2018 Jan-Mar;32(1):62-65. doi: 10.1016/j.sjopt.2018.02.018. Epub 2018 Mar 9.

5.

Optimization of a "bump-and-hole" approach to allele-selective BET bromodomain inhibition.

Runcie AC, Zengerle M, Chan KH, Testa A, van Beurden L, Baud MGJ, Epemolu O, Ellis LCJ, Read KD, Coulthard V, Brien A, Ciulli A.

Chem Sci. 2018 Jan 24;9(9):2452-2468. doi: 10.1039/c7sc02536j. eCollection 2018 Mar 7.

6.

Targeting of epigenetic regulators in neuroblastoma.

Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, Llort A, Hladun R, Roma J, Toledo JS, Gallego S, Segura MF.

Exp Mol Med. 2018 Apr 27;50(4):51. doi: 10.1038/s12276-018-0077-2. Review.

7.

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.

Wyce A, Matteo JJ, Foley SW, Felitsky DJ, Rajapurkar SR, Zhang XP, Musso MC, Korenchuk S, Karpinich NO, Keenan KM, Stern M, Mathew LK, McHugh CF, McCabe MT, Tummino PJ, Kruger RG, Carpenter C, Barbash O.

Oncogenesis. 2018 Apr 20;7(4):35. doi: 10.1038/s41389-018-0043-9.

8.

BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.

Morse MA, Balogh KK, Brendle SA, Campbell CA, Chen MX, Furze RC, Harada IL, Holyer ID, Kumar U, Lee K, Prinjha RK, Rüdiger M, Seal JT, Taylor S, Witherington J, Christensen ND.

Antiviral Res. 2018 Jun;154:158-165. doi: 10.1016/j.antiviral.2018.03.012. Epub 2018 Apr 11.

PMID:
29653131
9.

The Human Replicative Helicase, the CMG Complex, as a Target for Anti-cancer Therapy.

Seo YS, Kang YH.

Front Mol Biosci. 2018 Mar 29;5:26. doi: 10.3389/fmolb.2018.00026. eCollection 2018. Review.

10.

Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation.

Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J.

Eur J Med Chem. 2018 May 10;151:450-461. doi: 10.1016/j.ejmech.2018.04.006. Epub 2018 Apr 3.

PMID:
29649741
11.

Synthesis of a novel fused pyrrolodiazepine-based library with anti-cancer activity.

Malik N, Iyamu ID, Scheidt KA, Schiltz GE.

Tetrahedron Lett. 2018 Apr 11;59(15):1513-1516. doi: 10.1016/j.tetlet.2018.03.021. Epub 2018 Mar 8.

PMID:
29610541
12.

Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis.

Savitski MM, Zinn N, Faelth-Savitski M, Poeckel D, Gade S, Becher I, Muelbaier M, Wagner AJ, Strohmer K, Werner T, Melchert S, Petretich M, Rutkowska A, Vappiani J, Franken H, Steidel M, Sweetman GM, Gilan O, Lam EYN, Dawson MA, Prinjha RK, Grandi P, Bergamini G, Bantscheff M.

Cell. 2018 Mar 22;173(1):260-274.e25. doi: 10.1016/j.cell.2018.02.030. Epub 2018 Mar 15.

13.

Bromodomain and Extraterminal (BET) Proteins Regulate Hepatocyte Proliferation in Hepatocyte-Driven Liver Regeneration.

Russell JO, Ko S, Saggi HS, Singh S, Poddar M, Shin D, Monga SP.

Am J Pathol. 2018 Jun;188(6):1389-1405. doi: 10.1016/j.ajpath.2018.02.006. Epub 2018 Mar 12.

PMID:
29545201
14.

Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

Xiang Q, Zhang Y, Li J, Xue X, Wang C, Song M, Zhang C, Wang R, Li C, Wu C, Zhou Y, Yang X, Li G, Ding K, Xu Y.

ACS Med Chem Lett. 2018 Feb 13;9(3):262-267. doi: 10.1021/acsmedchemlett.8b00003. eCollection 2018 Mar 8.

PMID:
29541371
15.

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.

Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB.

Cancer Cell. 2018 Mar 12;33(3):401-416.e8. doi: 10.1016/j.ccell.2018.01.019.

PMID:
29533782
16.

BET bromodomain proteins regulate enhancer function during adipogenesis.

Brown JD, Feldman ZB, Doherty SP, Reyes JM, Rahl PB, Lin CY, Sheng Q, Duan Q, Federation AJ, Kung AL, Haldar SM, Young RA, Plutzky J, Bradner JE.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2144-2149. doi: 10.1073/pnas.1711155115. Epub 2018 Feb 14.

17.

BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition.

Andrieu GP, Denis GV.

Mol Cancer Res. 2018 Apr;16(4):580-586. doi: 10.1158/1541-7786.MCR-17-0568. Epub 2018 Feb 7.

PMID:
29437854
18.

BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis.

Dong X, Hu X, Chen J, Hu D, Chen LF.

Cell Death Dis. 2018 Feb 12;9(2):203. doi: 10.1038/s41419-017-0181-6.

19.

Gene-specific mechanisms direct glucocorticoid-receptor-driven repression of inflammatory response genes in macrophages.

Sacta MA, Tharmalingam B, Coppo M, Rollins DA, Deochand DK, Benjamin B, Yu L, Zhang B, Hu X, Li R, Chinenov Y, Rogatsky I.

Elife. 2018 Feb 9;7. pii: e34864. doi: 10.7554/eLife.34864.

20.

BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.

Hajmirza A, Emadali A, Gauthier A, Casasnovas O, Gressin R, Callanan MB.

Biomedicines. 2018 Feb 6;6(1). pii: E16. doi: 10.3390/biomedicines6010016. Review.

Supplemental Content

Support Center